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Extended Infusions of Meropenem for Febrile Neutropenia  
Daniel J Przybylski, PharmD and David J Reeves, PharmD, BCOP  
 
Abstract: 
Background: Neutropenic fever is an oncologic emergency that requires quick intervention with anti-pseudomonal beta-lactam 
antibiotics, such as meropenem. Previous literature suggests that extended infusions of beta-lactam antibiotics may improve clinical 
outcomes. To date, there are 3 prior studies utilizing an extended infusion beta-lactam in this population; however, there is only one 
previous study investigating the use of extended infusion meropenem in patients with febrile neutropenia. 
Objective: To describe the outcomes of eight patients receiving extended infusions of meropenem for the treatment of febrile 
neutropenia. 
Methods: A retrospective chart review was completed including adult patients admitted to a community teaching hospital who received 
extended infusions of meropenem for febrile neutropenia.  
Results: In this descriptive study, no patients receiving extended infusions of meropenem failed treatment, were readmitted for an 
infectious issue within 30 days, or endured inpatient mortality. Additionally, all eight patients defervesced within 48 hours, and four 
patients had a microbiologically documented infection. One patient incurred Clostridium difficile on day 2 of meropenem therapy. 
Conclusions: Extended infusions of meropenem may be effective in the treatment of febrile neutropenia. Future studies comparing 
extended infusions to intermittent infusions of meropenem for febrile neutropenia are warranted. 
 
 
INTRODUCTION 
Febrile neutropenia is a complication of cancer treatment and 
requires the use of broad spectrum antibiotics to treat 
potentially life-threatening infections. Anti-pseudomonal beta-
lactam antibiotics such as cefepime, piperacillin/tazobactam, or 
meropenem are first-line options in the treatment of febrile 
neutropenia.1 In general, efficacy for all beta-lactam antibiotics 
is enhanced when the concentrations of the antibiotics are four 
to five times greater than the organism’s minimum inhibitory 
concentration (MIC).2 In order to achieve favorable clinical 
outcomes, carbapenems (such as meropenem) require the time 
above the MIC to be at least 30-40% of the dosing interval.2 
Traditionally, meropenem is given every 6 or 8 hours with a 
standard 30 minute infusion to achieve this time above the MIC 
outcome; however, a Monte Carlo simulation in critically ill 
patients with febrile neutropenia with bacteremia suggests that 
extended infusions of meropenem increase its time above the 
MIC and thus the probability of target attainment (PTA) 
indicating extended infusions may have utility in the febrile 
neutropenia population.3 
Although this administration method seems like a promising 
alternative to the current standard, there is little clinical literature 
to support its use in the high risk setting of febrile neutropenia. 
Furthermore, the use of extended infusions renders the 
intravenous line unavailable for other medications, which is 
particularly problematic in those receiving several intravenous 
medications. Previously, a prospective study from 2017 in 
neutropenic patients compared extended and standard 
infusions of cefepime and found that there were comparable 
outcomes in regards to defervescence at 72 hours, clinical 
success, mortality, and length of stay.4 Of note, this prospective 
study demonstrated a potential decrease in the time to 
defervescence. In another retrospective trial of cefepime,  
 
 
patients receiving extended infusions were more likely to 
defervesce at 24 hours and time to defervescence was decreased 
by 14 hours compared to standard 30-minute infusions.5  
Likewise, piperacillin/tazobactam extended infusions 
demonstrated increased overall response (resolution of fever, 
sterile blood cultures, resolution of clinical signs and symptoms, 
and no need for change in antibiotic regimen) on day 4 in 
patients with febrile neutropenia.6  In the only published study 
evaluating extended infusions of meropenem for febrile 
neutropenia, treatment success after 5 days of meropenem was 
higher in those receiving the extended infusion.7  However, this 
study was limited to patients undergoing hematopoietic stem-
cell transplantation or induction chemotherapy for acute 
myeloid leukemia (AML).  Data in the general oncology 
population with febrile neutropenia is lacking.  The purpose of 
this retrospective, observational study is to describe the 
outcomes of extended infusion meropenem in patients with 
febrile neutropenia due to any cause. 
METHODS 
Study patients 
The local Institutional Review Board approved this retrospective, 
single center study. Adult patients admitted to a community 
teaching hospital with febrile neutropenia (ANC <500 cells and 
temperature ≥100.5° F) from August 2013 to March 2017 were 
included in this study if they received extended infusions of 
meropenem. Patients were excluded if defervescence occurred 
before meropenem was initiated. Per hospital protocol, patients 
receiving extended infusions received their first dose of 
meropenem over 30 minutes and subsequent doses were 
administered over 3 hours. If a patient incurred more than one 
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episode of febrile neutropenia during their hospital stay (i.e., 
became febrile after meeting criteria for defervescence – see 2.2 
Data collection below), only the first episode was included in this 
analysis.  
Data collection  
Demographic and clinical characteristics collected from the 
electronic health record for all eligible patients included age, sex, 
length of stay, serum creatinine, height, weight, documented 
past medical history, oncology diagnosis, duration of 
neutropenia, receipt of prior chemotherapy, use of prophylactic 
antibiotics, presence of documented mucositis, concomitant 
intravenous vancomycin usage, granulocyte colony stimulating 
factor (GCSF) administration, defervescence, time to 
defervescence, readmission within 30 days for an infectious 
issue, inpatient mortality, microbiologically documented 
infection, and antibiotic failure. Defervescence was defined as a 
temperature ≤100.4° F for at least 24 hours. Time to 
defervescence was defined as time from initiation of 
meropenem until defervescence. Antibiotic failure was defined 
as switching to another antibiotic for any reason other than 
allergy/intolerance or inpatient mortality due to febrile 
neutropenia. Additionally, Charlson Comorbidity Index Score 
and optimal renal dosing were determined for each patient. 
Optimal renal dosing was defined as meropenem 500 mg every 
6 hours for a creatinine clearance ≥50 ml/min, meropenem 500 
mg every 8 hours for a creatinine clearance between 25 and 49 
ml/min, meropenem 500 mg every 12 hours for a creatinine 
clearance between 10 and 24 ml/min, and meropenem 500 mg 
every 24 hours for a creatinine clearance ≤10 ml/min or on 
dialysis. Creatinine clearance was determined using the 
Cockcroft-Gault equation. 
RESULTS 
A total of eight patients were included in this descriptive study. 
Of these eight patients, five were female and three were male. 
Patient age ranged from 51 to 76 years and creatinine clearance 
ranged from 40 to 90 mL/min. Additionally, two patients 
received prophylaxis with ciprofloxacin, two patients received 
prophylaxis with sulfamethoxazole/trimethoprim, and the other 
four patients did not receive antibiotic prophylaxis. One patient 
received suboptimal renal dosing of meropenem. Additional 
patient characteristics are described in Table 1. Six of the eight 
patients had an oncologic diagnosis, one patient had 
myasthenia gravis, and the other patient had a history of kidney 
transplant and was receiving immunosuppressants. Table 2 
encompasses all patient diagnoses and their chemotherapy 
regimens, if applicable. 
No patients failed antibiotics, were readmitted for an infectious 
issue, or died during their hospital admission. Length of stay 
ranged from 4 to 53 days and time to defervescence ranged 
from 4 to 40.5 hours (average 21.6 hours). Four patients had a 
microbiologically documented infection, one of which incurred 
bacteremia. No patients experienced any adverse effects 
requiring meropenem discontinuation. Further patient 
outcomes and a description of microbiologically documented 
infections are described in Table 3 and Table 4, respectively. 
 
Table 1: Patient Characteristics  
Patient number 1 2 3 4 5 6 7 8 
Sex Male Female Female Female Male Female Female Male 
Age, years 69 51 65 64 72 60 55 76 
Weight, kg 85 72 60 105 92 56 87 96 
Baseline CrCl, mL/min 58 71 45 81 69 68 90 40 
Optimal renal dosing* Yes Yes Yes Yes Yes Yes Yes No 
CCS 2 8 2 1 3 2 2 2 
Mucositis No No No No No Yes No No 
Prior prophylactic 
antibiotic 
None None None None Cipro SMX/TMP Cipro SMX/TMP 
Duration of neutropenia, 
days 
5 11 20 6 5 26 2 4 
Concomitant Vancomycin No Yes Yes Yes No Yes Yes Yes 
Concomitant GCSF No Yes Yes No No No Yes Yes 
Abbreviations: CCS: Charlson Comorbidity Index Score; Cipro: ciprofloxacin; SMX/TMP: sulfamethoxazole/trimethoprim; GCSF: 
granulocyte colony stimulating factor 
*At the time of drug initiation 
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Table 2: Diagnosis and current treatment 
Patient number Diagnosis Chemotherapy regimen 
1 Breast cancer Docetaxel + cyclophosphamide 
2 Burkitt’s lymphoma Hyper-CVAD+R 
3 B-cell ALL Hyper-CVAD+R+MTX/ARA-C IT 
4 Myasthenia gravis N/A 
5 AML HiDAC 
6 AML 7+3 
7 Breast cancer Docetaxel + cyclophosphamide 
8 Kidney transplant N/A 
Abbreviations: Hyper-CVAD: cyclophosphamide, mesna, vincristine, doxorubicin, dexamethasone;  R: rituximab; MTX+ARA-C: 
methotrexate and cytarabine; IT: intrathecal; HiDAC: high dose cytarabine; 7+3 7 days of cytarabine and 3 days of idarubicin 
 
Table 3: Patient Outcomes  
Patient 
number 
1 2 3 4 5 6 7 8 
Length of stay, 
days 
10 53 26 17 11 47 5 4 
Readmission 
for an 
infectious 
issue within 
30 days 
No No No No No No No No 
Inpatient 
mortality 
No No No No No No No No 
Time to 
defervescence, 
hours 
32 14 40.5 5.5 40 27 9.5 4 
Duration of 
antibiotics, 
days 
2 6 8.3 3 4.3 11 3 2 
Antibiotic 
failure 
No No No No No No No No 
 
 
 
 
 
 
 
Table 4: Microbiologically documented infections  
Study 
number 
Organism Culture 
site 
Resistance 
1 
Clostridium difficile Stool 
Pan-
susceptible 
2 Pseudomonas 
aeruginosa 
Abscess 
Pan-
susceptible 
3 N/A   
4 Staphylococcus 
aureus 
Wound 
Pan-
susceptible 
5 N/A   
6 Streptococcus 
viridans 
Blood 
Pan-
susceptible 
7 N/A   
8 N/A   
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DISCUSSION 
Neutropenic fever is an oncologic emergency that requires swift 
intervention with broad spectrum antibiotics. Meropenem is 
commonly used for febrile neutropenia, especially as a step up 
therapy after other antibiotics (e.g. cefepime, 
piperacillin/tazobactam) have failed or in patients at risk for or 
with a history of resistant organisms. Previous literature has tried 
to optimize meropenem dosing based on its pharmacokinetic 
and pharmacodynamic profile. When compared to meropenem 
1000 mg every 8 hours over 30 minutes, meropenem 500 mg 
every 6 hours over 30 minutes achieved higher PTA for 
susceptible pathogens in a pharmacokinetic study from 2005.8 
Additionally, meropenem 500 mg every 6 hours administered 
over 30 minutes produced similar outcomes to meropenem 
1000 mg every 8 hours administered over 30 minutes in a study 
applying population pharmacokinetic and Monte Carlo 
simulations.9 A separate Monte Carlo simulation evaluated 1 g 
of meropenem administered over either 30 minutes or 3 hours.3 
When aiming for a time over the MIC of 40%, the PTA for 
pathogens with a MIC of 4 was 75.7% with intermittent infusions 
and 99.2% with extended infusions.3 When looking at the same 
outcome for a MIC of 8, the study demonstrated a PTA of 17.8% 
with intermittent infusions and 78.8% with extended infusions.3 
This increased PTA is especially important for organisms 
harboring resistance mechanisms, such as Pseudomonas 
aeruginosa and Acinetobacter spp..3,10,11 The previously 
mentioned Monte Carlo simulation also demonstrated a 
marginal increase in PTA with extended infusions of meropenem 
for both Pseudomonas aeruginosa (77.1% v. 79.3%) and 
Acinetobacter spp. (75.8% v. 78%) infections.3 In the current 
study, meropenem 500 mg every 6 hours infused over 3 hours 
was administered to patients with febrile neutropenia. 
Beta-lactam antibiotics have previously shown benefit in other 
patient populations by extending the infusion time over a period 
of three or four hours compared to a standard 30-minute 
infusion.12-16 However, subgroup analyses of carbapenems have 
not shown benefit in ICU patients or patients with pneumonia.13-
15,17 In a meta-analysis of continuous or extended infusions of 
carbapenems or piperacillin/tazobactam for pneumonia or 
infections in ICU patients, carbapenems did not significantly 
reduce the risk of mortality (RR 0.66, 95% CI 0.34 – 1.30).13 
Additionally, another meta-analysis of continuous or extended 
infusions of beta-lactam antibiotics in ICU patients indicated 
extended infusions of carbapenems did not reduce mortality (RR 
0.74, 95% CI 0.42 – 1.28) or increase the rate of clinical success 
(RR 1.16, 95% CI 0.93 – 1.46).14 In the same fashion, a meta-
analysis of patients with nosocomial pneumonia receiving 
continuous or extended infusions of anti-pseudomonal beta-
lactam antibiotics showed no statistical increase in clinical cure 
(OR 2.01, 95% CI 0.48 – 8.37) or statistical decrease in mortality 
(OR 0.92, 95% CI 0.57-1.47) when using extended infusions of 
carbapenems.15 Moreover, a meta-analysis of randomized 
controlled trials including any hospitalized patient receiving 
extended infusions of a beta-lactam antibiotic showed no 
benefit for extended infusions in either mortality (RR 0.92, 95% 
CI 0.61 – 1.37) or clinical cure (RR 1.00, 95% CI 0.94 – 1.06).17 
Again, further subgroup analyses found no benefit with 
extended infusions of carbapenems in regards to mortality (RR 
1.08, 95% CI 0.64 – 1.82) or clinical cure (RR 1.00, 95% CI 0.92 – 
1.10).17  
In patients with febrile neutropenia, limited data exists 
supporting the use of extended infusion beta-lactams or 
carbapenems.  A prospective study of febrile neutropenia 
compared extended and intermittent infusions of cefepime 2 g 
every 8 hours and observed no difference in defervescence at 
24, 48, or 72 hours or time to defervescence.4 Only 63% of 
patients receiving extended infusions of cefepime defervesced 
at 48 hours and the median time to deferevescence was 19 
hours. Of note, this prospective study only included hematologic 
malignancies and stem cell transplant patients. Additionally, 
patients were excluded if they met diagnostic criteria for sepsis 
or had a creatinine clearance <50 mL/min. In a retrospective 
study of cefepime extended infusions in oncology patients with 
febrile neutropenia, those receiving extended infusions were 
more likely to defervesce at 24 hours and time to defervescence 
was decreased by 14 hours.5  Upon multivariate analysis, the 
odds of defervescence at 24 hours were quadrupled with 
extended infusions.  Extended infusion piperacillin/tazobactam 
was also studied prospectively in patients with febrile 
neutropenia while undergoing hematopoietic stem cell 
transplant or induction/consolidation therapy for acute 
leukemia.6  In that study, extended infusion piperacillin-
tazobactam increased the likelihood of overall response 
(resolution of fever, sterile blood cultures, resolution of clinical 
signs and symptoms, and no need for change in antibiotic 
regimen) (74.4% extended infusion vs. 55.1% standard infusion, 
p = 0.044).   
In the only published study of extended infusion meropenem in 
the setting of febrile neutropenia, patients undergoing 
hematopoietic stem-cell transplantation or induction chemo-
therapy for AML were more likely to achieve treatment success 
(resolution of fever for ≥ 24 h, resolution or improvement in 
clinical signs and symptoms of infection, absence of persistent 
or breakthrough bacteremia, and no additional antibiotics 
prescribed) at 5 days if they received extended infusions (68.4% 
extended infusion vs. 40.9% standard infusion, p<0.001).7 In 
addition, patients receiving extended infusion meropenem had 
a more prompt defervescence (p=0.021).  In the current study, 
extended infusions of meropenem appeared to be effective in 
all eight patients. All patients defervesced within 48 hours of 
meropenem administration and the median time to 
defervescence was 20.5 hours. Additionally, no patients required 
an escalation in antibiotic therapy, were readmitted for an 
infectious issue within 30 days of discharge, or passed away 
during their hospital stay.  Although febrile neutropenia most 
commonly occurs in the leukemic populations, patients in this 
study had a variety of oncologic diagnoses including AML, ALL, 
Burkitt’s lymphoma, and breast cancer. Furthermore, one patient 
had myasthenia gravis and another was on chronic immuno-
suppression for a past kidney transplant. The variety of 
diagnoses demonstrates that extended infusions of meropenem 
may be effective in diverse patient populations who incur febrile 
neutropenia. Additionally, four patients had a microbiologically 
documented infection, one of which was Clostridium difficile and 
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occurred while on day 2 of meropenem. No resistance patterns 
were identified in any of the documented infections. Of note, in 
the prior study of meropenem extended infusion, 55% of the 
patients with microbiologically documented infections had 
meropenem-resistant microorganisms compared to none in the 
current descriptive study.7  To the authors’ knowledge, this is the 
first description of meropenem extended infusion in the general 
population with febrile neutropenia.   
CONCLUSION 
Febrile neutropenia has traditionally been treated with 
intermittent infusions of beta-lactam antibiotics. Due to the 
potential life-threatening nature of this oncologic complication, 
it is important to identify effective interventions, including 
optimal antibiotic administration techniques. In this descriptive 
study, extended infusions of meropenem appeared to be 
effective for the treatment of febrile neutropenia, without any 
instances of antibiotic failure. Further comparative studies with 
intermittent infusions in this general population of patients with 
febrile neutropenia are warranted. 
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